title: [Our therapy concept in nonresectable liver metastases].
abstract: Cytotoxic chemotherapy was performed in a total of 18 patients (12 men, 6 women): 5 patients with colonic carcinoma and 1 patient with unknown primary lesion received 5 x 1000 mg 5-Fluorouracil (5-FU) at 4 week interval. The 5 following patients primarily suffering from colonic carcinoma were treated with 0.5 mg/kg BW FUDR continuously at 2 week interval. 5 further patients with colonic carcinoma sequential received Mitomycin C (8 mg/m2) and 4 x 1000 mg 5-FU. 2 patients with breast cancer were treated with 500 mg/m2 Cyclophosphamide, the same amount of 5-FU and 40 mg/m2 Methotrexate every 4 weeks. Chemotherapy was well tolerated by all patients. A clinically significant response, however, was seen in only 2 patients with breast cancer. In 8 patients a liver transplantat was performed, which was followed in 3 cases by ultra-high dose Cyclosphosphamide, lethal total body irradiation and autologous bone marrow transplantation. 1 further patient received polychemotherapy. At the time of this analysis only 3 patients were still alive at 61, 30 and 26 months with only 1 perioperative death. All 3 had meanwhile developed recurrent or metastatic disease. Because of these sobering results, liver transplantation for the treatment of non-resectable liver metastases has been abandoned, and regional chemotherapy is now only applied in patients with liver metastases from breast cancer and after resection of metastases in an adjuvant setting.
authors.affiliation: I. Universitätsklinik für Chirurgie Innsbruck.
authors.forename: R
authors.initials: R
authors.lastname: Margreiter
authors.forename: T
authors.initials: T
authors.lastname: Schmid
authors.forename: E
authors.initials: E
authors.lastname: Steiner
authors.forename: F
authors.initials: F
authors.lastname: Aigner
authors.forename: P
authors.initials: P
authors.lastname: Then
authors.forename: H
authors.initials: H
authors.lastname: Pernthaler
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007260:Infusion Pumps; D007261:Infusions, Intra-Arterial / Q000295:instrumentation*; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D008937:Mitomycins; D005467:Floxuridine; D016685:Mitomycin; D005472:Fluorouracil
vernacular_title: Unser Therapiekonzept bei nichtresezierbaren Lebermetastasen.